Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Myeloid, Acute 1Gastrointestinal Stromal Tumors 1

Interventions

Cyclophosphamide 29fludarabine phosphate 22Whole-Body Irradiation 20Mycophenolic Acid 20fludarabine 19asciminib 19nilotinib 16Tacrolimus 13Imatinib Mesylate 13Melphalan 11Dasatinib 9Sirolimus 8Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Granulocyte Colony-Stimulating Factor 7Busulfan 7bosutinib 6Mesna 6Cyclosporine 6ponatinib 5Stem Cell Transplantation 5Filgrastim 5venetoclax 4ruxolitinib 4blinatumomab 4Specimen Handling 4Cyclosporins 4thymoglobulin 3Bone Marrow Transplantation 3Antilymphocyte Serum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × olverembatinib × 1 year × Clear all
NCT06817720 2026-05-20

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07383298 2026-02-03

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

Peking University People's Hospital

Enrolling by invitation
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡